Novo CEO Mike Doustdar and Lilly CEO David Ricks announced US pricing deals for GLP-1 agonists in obesity during a White House event. (Screenshot of White House Broadcast)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
